A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis

by | Aug 4, 2021 | Exploring Mocravimod Key Research Highlights

https://priothera.com/a-multicentre-double-blind-placebo-controlled-parallel-group-study-to-evaluate-the-efficacy-safety-and-tolerability-of-the-s1p-receptor-agonist-krp203-in-patients-with-moderately-active-refractor/